{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T15:32:10Z","timestamp":1717947130498},"reference-count":2,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T00:00:00Z","timestamp":1412294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11,1]]},"abstract":"<jats:p>The U.S. Food and Drug Administration's accelerated approval of omacetaxine mepesuccinate for the treatment of chronic-phase or accelerated-phase chronic myeloid leukemia has been converted to full approval. Approved changes to the omacetaxine administration guidelines to allow home administration using syringes prepared by a health care professional will improve patient access to treatment by alleviating the need for daily visits to a medical facility during treatment, while also addressing concerns regarding the ability of patients or caregivers to accurately prepare and administer injections safely.<\/jats:p>","DOI":"10.1634\/theoncologist.2014-0230","type":"journal-article","created":{"date-parts":[[2014,10,4]],"date-time":"2014-10-04T04:35:25Z","timestamp":1412397325000},"page":"e14-e14","source":"Crossref","is-referenced-by-count":4,"title":["Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate"],"prefix":"10.1093","volume":"19","author":[{"given":"Ann Q.","family":"Shen","sequence":"first","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Munteanu","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., Frazer, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna Jean","family":"Khoury","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,10,3]]},"reference":[{"key":"2021122309064777200_B1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","article-title":"U.S. Food and Drug Administration approval summary: Omacetaxine mepesuccinate as treatment for chronic myeloid leukemia","volume":"19","author":"Alvandi","year":"2014","journal-title":"The Oncologist"},{"key":"2021122309064777200_B2","volume-title":"Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use [prescribing information]","year":"2014"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/11\/e14\/41862094\/oncolo_19_11_e14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/11\/e14\/41862094\/oncolo_19_11_e14.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T09:08:43Z","timestamp":1640250523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/11\/e14\/6399381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,3]]},"references-count":2,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,10,3]]},"published-print":{"date-parts":[[2014,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0230","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,11,1]]},"published":{"date-parts":[[2014,10,3]]}}}